Nutriband Granted Patent in Macao for its AVERSA Abuse Deterrent Transdermal Technology
Nutriband Inc. (NASDAQ:NTRB) has secured a patent in Macao for its AVERSA abuse deterrent transdermal technology. The patent, J/9010, was granted on February 11, 2025, protecting the company's 'Abuse and Misuse Deterrent Transdermal Systems.'
AVERSA technology is now protected by patents in 46 countries, including major markets like the US, Europe, Japan, and China. The technology incorporates aversive agents into transdermal patches to prevent abuse of drugs with high abuse potential, such as opioids and stimulants.
The company is collaborating with Kindeva Drug Delivery to develop AVERSA Fentanyl, potentially the first abuse-deterrent opioid patch globally. The product aims to deter abuse and reduce accidental exposure risks, with projected peak annual US sales between $80 million to $200 million.
Nutriband Inc. (NASDAQ:NTRB) ha ottenuto un brevetto a Macao per la sua tecnologia transdermica deterrente per l'abuso AVERSA. Il brevetto, J/9010, è stato concesso l'11 febbraio 2025, proteggendo i 'Sistemi Transdermici per la Prevenzione dell'Abuso e dell'Uso Improprio' dell'azienda.
La tecnologia AVERSA è ora protetta da brevetti in 46 paesi, inclusi mercati principali come gli Stati Uniti, l'Europa, il Giappone e la Cina. La tecnologia incorpora agenti aversivi nei cerotti transdermici per prevenire l'abuso di farmaci con un alto potenziale di abuso, come gli oppioidi e gli stimolanti.
L'azienda sta collaborando con Kindeva Drug Delivery per sviluppare AVERSA Fentanyl, potenzialmente il primo cerotto oppioide deterrente per l'abuso a livello globale. Il prodotto mira a scoraggiare l'abuso e a ridurre i rischi di esposizione accidentale, con vendite annuali massime previste negli Stati Uniti tra $80 milioni e $200 milioni.
Nutriband Inc. (NASDAQ:NTRB) ha obtenido una patente en Macao para su tecnología transdérmica AVERSA, diseñada para prevenir el abuso. La patente, J/9010, fue concedida el 11 de febrero de 2025, protegiendo los 'Sistemas Transdérmicos para la Prevención del Abuso y Uso Indebido' de la compañía.
La tecnología AVERSA ahora está protegida por patentes en 46 países, incluidos mercados importantes como EE. UU., Europa, Japón y China. La tecnología incorpora agentes aversivos en parches transdérmicos para prevenir el abuso de medicamentos con alto potencial de abuso, como opioides y estimulantes.
La empresa está colaborando con Kindeva Drug Delivery para desarrollar AVERSA Fentanyl, que podría ser el primer parche de opioides con efecto deterrente a nivel mundial. El producto tiene como objetivo disuadir el abuso y reducir los riesgos de exposición accidental, con ventas anuales máximas proyectadas en EE. UU. entre $80 millones y $200 millones.
뉴트리밴드 주식회사 (NASDAQ:NTRB)는 마카오에서 AVERSA 남용 방지 경피 기술에 대한 특허를 확보했습니다. 이 특허(J/9010)는 2025년 2월 11일에 부여되었으며, 회사의 '남용 및 오용 방지 경피 시스템'을 보호합니다.
AVERSA 기술은 이제 46개국에서 특허로 보호되며, 미국, 유럽, 일본, 중국과 같은 주요 시장을 포함합니다. 이 기술은 경피 패치에 혐오제를 포함시켜 오피오이드 및 자극제와 같은 남용 가능성이 높은 약물의 남용을 방지합니다.
회사는 Kindeva Drug Delivery와 협력하여 AVERSA 펜타닐을 개발하고 있으며, 이는 전 세계 최초의 남용 방지 오피오이드 패치가 될 가능성이 있습니다. 이 제품은 남용을 억제하고 우발적 노출 위험을 줄이는 것을 목표로 하며, 미국에서의 예상 연간 최대 판매액은 $8000만에서 $2억 사이입니다.
Nutriband Inc. (NASDAQ:NTRB) a obtenu un brevet à Macao pour sa technologie transdermique AVERSA, conçue pour prévenir l'abus. Le brevet, J/9010, a été accordé le 11 février 2025, protégeant les 'Systèmes Transdermiques de Prévention de l'Abus et de l'Utilisation Inappropriée' de la société.
La technologie AVERSA est désormais protégée par des brevets dans 46 pays, y compris des marchés majeurs tels que les États-Unis, l'Europe, le Japon et la Chine. La technologie intègre des agents aversifs dans des patchs transdermiques pour prévenir l'abus de médicaments à fort potentiel d'abus, tels que les opioïdes et les stimulants.
La société collabore avec Kindeva Drug Delivery pour développer AVERSA Fentanyl, qui pourrait être le premier patch opioïde dissuasif au monde. Le produit vise à dissuader l'abus et à réduire les risques d'exposition accidentelle, avec des ventes annuelles maximales projetées aux États-Unis entre 80 millions et 200 millions de dollars.
Nutriband Inc. (NASDAQ:NTRB) hat ein Patent in Macau für seine AVERSA-Technologie zur Verhinderung von Missbrauch gesichert. Das Patent, J/9010, wurde am 11. Februar 2025 erteilt und schützt die 'Transdermalen Systeme zur Verhinderung von Missbrauch und Fehlgebrauch' des Unternehmens.
Die AVERSA-Technologie ist nun in 46 Ländern durch Patente geschützt, darunter wichtige Märkte wie die USA, Europa, Japan und China. Die Technologie integriert aversive Substanzen in transdermale Pflaster, um den Missbrauch von Arzneimitteln mit hohem Missbrauchspotenzial, wie Opioiden und Stimulanzien, zu verhindern.
Das Unternehmen arbeitet mit Kindeva Drug Delivery zusammen, um AVERSA Fentanyl zu entwickeln, das potenziell das erste missbrauchsverhindernde Opioid-Pflaster weltweit sein könnte. Das Produkt zielt darauf ab, Missbrauch zu verhindern und das Risiko einer versehentlichen Exposition zu reduzieren, mit prognostizierten jährlichen Höchstverkäufen in den USA zwischen 80 Millionen und 200 Millionen US-Dollar.
- Patent portfolio expansion to 46 countries strengthens global intellectual property protection
- Partnership with established manufacturer Kindeva Drug Delivery for product development
- Significant market potential with projected annual US sales of $80-200 million for AVERSA Fentanyl
- First-mover advantage in abuse-deterrent opioid patch market
- Product still in development phase with no immediate revenue generation
- Market projections are estimates with no guaranteed success
- Dependent on external manufacturing partner for product development
Insights
This patent grant in Macao represents another significant addition to Nutriband's already robust global intellectual property portfolio for its AVERSA technology. With patents now secured in 46 countries including major pharmaceutical markets, Nutriband has constructed a formidable protective barrier around its abuse-deterrent transdermal technology.
The strategic value of this protection cannot be overstated in the pharmaceutical sector, where IP assets often constitute the primary value driver. By securing patents across diverse global jurisdictions, Nutriband has effectively created multiple layers of defense against potential competitors who might attempt to develop similar abuse-deterrent transdermal technologies.
For context, building this type of comprehensive global patent architecture is exactly what successful pharmaceutical companies require before major partners or acquirers typically show serious interest. The specific Macao patent strengthens Nutriband's position in the broader Asian market, complementing existing protections in mainland China, Hong Kong, Japan, and Korea.
What's particularly notable here is the scope of protection around a technology addressing the critical public health issue of opioid abuse. The AVERSA platform technology has applications beyond just fentanyl, potentially extending to multiple drugs with abuse potential, creating a pipeline of protected opportunities rather than just a single product.
The market opportunity for Nutriband's AVERSA Fentanyl product warrants attention considering the company's current
The abuse-deterrent opioid market addresses a critical public health need while facing increasing regulatory support. Fentanyl specifically represents a high-priority target for abuse deterrence given its potency and associated mortality risks. What makes this opportunity distinctive is the transdermal delivery system – most existing abuse-deterrent technologies focus on oral formulations, leaving a gap in the market for safer patch-based delivery.
The partnership with Kindeva adds credibility, as Kindeva brings established expertise in transdermal drug delivery systems and manufacturing capabilities. This collaboration significantly reduces execution risk around the physical production of these specialized patches.
While this patent grant doesn't accelerate the timeline to commercialization, it does strengthen the commercial potential by extending market exclusivity. For investors, the primary value inflection points remain clinical development milestones and FDA regulatory decisions, though this expanding IP portfolio enhances the foundation for future revenue streams. The technology's ability to maintain legitimate patient access while deterring abuse represents a balanced approach that should appeal to prescribers, patients, and regulators alike.
Nutriband granted patent protecting its AVERSA abuse deterrent platform technology in Macao, a Special Administrative Region of the People’s Republic of China
ORLANDO, Fla., April 11, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has received notification that its patent has been granted in Macao for its patent entitled, "Abuse and Misuse Deterrent Transdermal Systems," which protects its AVERSA™ abuse deterrent transdermal technology.
The Macao Intellectual Property Office granted patent J/9010 on February 11, 2025 as recorded in Macao Official Bulletin No. 10 on March 5, 2025. Macao is a Special Administrative Region (SAR) of the People’s Republic of China that has its own patent system and patent laws which are separate and distinct from those of mainland China.
The AVERSA™ abuse deterrent technology is now covered by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia as well as two regions of China: Hong Kong and Macao.
Nutriband’s AVERSA™ abuse-deterrent technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential including opioids and stimulants. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse while making sure that these drugs remain accessible to those patients who really need them.
Nutriband is currently working with its partner Kindeva Drug Delivery, a leading global contract development and manufacturing organization focused on drug-device combination products, to develop its lead product, AVERSA™ Fentanyl, which incorporates Nutriband’s AVERSA™ abuse-deterrent transdermal technology into Kindeva’s FDA-approved transdermal fentanyl patch system.
AVERSA Fentanyl has the potential to be the world’s first abuse-deterrent opioid patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl patches. AVERSA Fentanyl has the potential to reach peak annual US sales of
____________________________________________________
1 Health Advances AVERSA Fentanyl market analysis report 2022
About AVERSA™ Abuse-Deterrent Transdermal Technology
Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.
About Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.
Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Form 10-K for the year ended January 31, 2024, filed May 1, 2024, the Forms 10-Q’s filed subsequent to the Form 10-K in 2024, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
Contact Information:
Nutriband Inc.
Phone: 407-377-6695
Email: Support@nutriband.com
SOURCE: Nutriband Inc.
FAQ
What is the potential market value for Nutriband's (NTRB) AVERSA Fentanyl product?
How many countries have granted patents for Nutriband's (NTRB) AVERSA technology?
What is the purpose of Nutriband's (NTRB) AVERSA technology in transdermal patches?
When was Nutriband's (NTRB) AVERSA patent granted in Macao?
Who is Nutriband's (NTRB) development partner for AVERSA Fentanyl?
